MedTrace Logo

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

NCT05465343 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-12-19

No results posted yet for this study

Summary

This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Conditions

Interventions

DRUG

Furmonertinib 160 mg, Q.D.

Furmonertinib 160 mg orally once daily in previously treated groups

Sponsors & Collaborators

  • Peking Union Medical College

    lead OTHER

Principal Investigators

  • Junling Li, Professor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2025-12-12
Completion
2025-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465343 on ClinicalTrials.gov